
{{Act of Congress
| congress       = 113
| session        = 1
| pl             = 1
| title          = 
| override_previous = 
| statvolume     = 
| statpage       = 
| year           = 2013
| month          = 01
| day            = 23
| bill           = 413
| billtype       = hr
| notes          = 
| resolution     = 
| purpose        = To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 413}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|January 23, 2013}}


{{Center|
[[Wikipedia:Peter Welch|Mr. Welch ]](for himself, 
[[Wikipedia:Richard L. Hanna|Mr. Hanna ]], 
[[Wikipedia:Jim Cooper|Mr. Cooper ]], and 
[[Wikipedia:Bruce Braley|Mr. Braley of Iowa ]]) introduced the following bill; which was referred to the [[Wikipedia:United States House Committee on Energy and Commerce|Committee on Energy and Commerce ]], and in addition to the Committee on [[Wikipedia:United States House Committee on Ways and Means|Ways and Means ]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}


{{Center|A BILL}}

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
1. Eliminating the 2-year delay in implementation of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system


Section 632(b) of the American Taxpayer Relief Act of 2012 ( Public Law 112–240 ) is amended by striking all that precedes “With respect to the implementation ”and inserting the following::


=(b) Monitoring of implementation of oral-Only ESRD-Related drugs in the ESRD prospective payment system=

With respect to the implementation.
